Loading patent…
AssigneeHuman Genome Sciences, Inc.
InventorsTheodora Salcedo, Steven M. Ruben, Craig A. Rosen, Vivian R. Albert, Claire Dobson, Tristan Vaughan
Estimating the term…
The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.
An isolated antibody or fragment thereof comprising amino acid residues 26–35, 50–66, 99–107, 157–170, 186–192, and 225–234 of SEQ ID NO:43, wherein said antibody or fragment thereof immunospecifically binds a TR4 protein selected from the group consisting of:
An isolated antibody or fragment thereof comprising ammo acid residues 1–118 and 135–245 of SEQ ID NO:43, wherein said antibody or fragment thereof immunospecifically binds a TR4 protein selected from the group consisting of:
An isolated scFv comprising amino acid residues 1 to 245 of SEQ ID NO:43.
The antibody expressed by the cell line of ATCC Deposit PTA-3570.
An isolated antibody or fragment thereof comprising an amino acid sequence selected from the group consisting of:
An isolated antibody or fragment thereof comprising amino acid residues 1–118 and 135–245 of SEQ ID NO:42, wherein said antibody or fragment thereof immunospecifically binds a TR4 protein selected from the group consisting of:
An isolated antibody or fragment thereof comprising an amino acid sequence selected from the group consisting of:
An isolated antibody selected from the group consisting of:
Dependencies are inferred from the claim text.